On Dec. 19, 2022, the U.S. Food & Drug Administration (FDA) approved subcutaneous abaloparatide (Tymlos) for the treatment of men with osteoporosis at high risk of fracture https://t.co/igwxVCdKuo https://t.co/COSmDrsv4p

Alternatives to Vagal nerve stimulation Dr Eric Ruderman #RWCS23 @RWCSmtg https://t.co/zpJsh10LLQ

2nd study results with Implantable Vagal nerve stim in active #RA pts. Dr Eric Ruderman #RWCS23 https://t.co/S6aFSVjePD

Implantable Vagal nerve stimulation studied in 17 active #RA pts DAS ~6. Dr Eric Ruderman #RWCS23 https://t.co/Xn9Ur199nv

Dr Eric Ruderman #RWCS23 Bee Venom around since 1859, vaguely better than placebo https://t.co/3Xl7SZwQPm

ADA biosimilars: one is out now and seven due out by July. “It’s time to get onboard with biosimilars” @RheumNow @RWCSmtg #RWCS23

Do you use TNFi in pregnant patients? @RheumNow #RWCS23 @RWCSmtg

Low dose prednisolone in RA. GLORIA shows toxicity can be a real issue. @RWCSmtg @RheumNow #RWCS23 https://t.co/KstyKdjWn2

2022 EULAR recs for RA treatment @RheumNow @RWCSmtg #RWCS23 https://t.co/nWCcFJyIhz

Join us on 3/18 and 3/19 in Dallas, Texas, or virtually for RheumNow Live! Among our 24 speakers, Dr. Sergio and Monica Schwartzman will cover All in the Family Rheumatology. Dr. Philip Conaghan will cover Insights into the Future of OA and more. https://t.co/gAKQYxhTMY https://t.co/zMOGfhRrg2